Prospective Studies

A Nimble, Experienced Team Built to Help You Optimize Results

It's our goal to help you uncover evidence that delivers the greatest impact for your product. Xcenda implements innovative and creative approaches to projects while still stringently adhering to good clinical practices, FDA regulations, and international standards. With a more streamlined protocol and focus on only the most relevant patient recruitment sources, we’re able to get the most for your real-world evidence investment with greater cost efficiencies and quicker results.

Support your value story with innovative real-world evidence approaches.

Real-world evidence (RWE) has become a veritable necessity for continued commercial success. The 21st Century Cures Act, passed in 2016, places additional focus on the use of real-world data to support regulatory decision-making, including both drug approvals and new indications for approved drugs. Knowing the value of RWE is one thing. But how do manufacturers realistically gather—and integrate—data that supports their product value story, both pre-and post-launch?
Read article

Case Study

Addressing an Evidentiary Gap With Real-World Prospective Studies

Learn how we helped one client address an evidence gap for a revolutionary new orphan drug.
Read more

Meet the Expert

Kim McLeod, MPH

Kim McLeod, MPH, is a Senior Director and leads Prospective Research within the Real World Evidence (RWE) team at Xcenda. In this role, she leads a team that supports RWE engagements that include the design and execution of retrospective chart reviews and prospective clinical studies. 
Kim McLeod

Start a Conversation

We’re value drivers and problem solvers. Let us connect you with experts who understand your world and what success demands.
Contact us